Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations

被引：0

作者：

Garmezy, B. ^{[1
]}

Borad, M. ^{[2
]}

Lin, C. C. ^{[3
]}

Chen, L. T. ^{[4
]}

Perez, C. A. ^{[5
]}

Kato, S. ^{[6
]}

Tam, B. ^{[7
]}

Severson, P. ^{[8
]}

Quah, C. S. ^{[9
]}

Harding, J. J. ^{[10
]}

机构：

[1] Sarah Cannon Res Inst, Res, Nashville, TN USA

[2] Mayo Clin, Ctr Canc, Oncol Dept, Scottsdale, AZ USA

[3] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[4] Kaohsiung Med Univ, Chung Ho Mem Hosp, Hematol Dept, Kaohsiung, Taiwan

[5] Florida Canc Specialists, Med Oncol, Ft Myers, FL USA

[6] Univ Calif San Diego UCSD, Med Oncol, La Jolla, CA USA

[7] Kinnate Biopharma, Clin Sci, San Diego, CA USA

[8] Kinnate Biopharma Inc, Translat Med, San Diego, CA USA

[9] Kinnate Biopharma, Clin Dev, San Diego, CA USA

[10] Mem Sloan Kettering Evelyn H Lauder Breast Ctr, Med, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1423

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

130P

引用

页码：S231 / S232

页数：2

共 46 条

[31] ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer
Kamath, Suneel
Tai, David
Moreno, Irene
Babiker, Hani
Jin, Zhaohui
Yoo, Changhoon
Ricard, Fabien
Jen, Kai Yu
Coward, Jim
Liu, Jia
Opdam, Frans
Millward, Michael
Ponz-Sarvise, Mariano
Yachnin, Jeffrey
Kim, Richard
Park, Joon Oh
Subbiah, Vivek
Schram, Alison M.
CANCER RESEARCH, 2023, 83 (05)
[32] A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201).
Rodon Ahnert, Jordi
Roychowdhury, Sameek
Ellis, Haley
Blanco, Fernando F.
Burn, Timothy
Davis, Jennifer Michelle
Balcer, Alex
Zalutskaya, Alena
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS646 - TPS646
[33] PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.
Abou-Alfa, Ghassan K.
Borbath, Ivan
Roychowdhury, Sameek
Goyal, Lipika
Lamarca, Angela
Macarulla, Teresa
Shroff, Rachna T.
Oh, Do-Youn
Javle, Milind M.
Tamas, Catalin
Savastano, David M.
Van Veenhuyzen, David Friedrich
Xu, Cindy
Solanas, Jacki
Freas, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 516 - 516
[34] A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
Piha-Paul, Sarina Anne
Hierro, Cinta
Boni, Valentina
Moreno, Victor
Hahn, Noah M.
Bitting, Rhonda L.
Bauer, Todd Michael
Aggarwal, Rahul Raj
Gourlay, Steven
Smith, Patrick
Venetsanakos, Eleni
Meric-Bernstam, Funda
Brameld, Ken
Karr, Dane
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
Piha-Paul, Sarina Anne
Hierro, Cinta
Funk, Jens Oliver
Gourlay, Steven
Smith, Patrick
Venetsanakos, Eleni
Meric-Bernstam, Funda
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[36] A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations.
Pant, Shubham
Tabernero, Josep
Massard, Christophe
Iyer, Gopa
Witt, Olaf
Doi, Toshihiko
Qin Shukui
Lu-Emerson, Christine
Hargrave, Darren R.
Garcia-Corbacho, Javier
Little, Shonda Marie
Xia, Qi
Santiago-Walker, Ademi E.
Moy, Christopher
Hammond, Constance
Sweiti, Hussein
Schuler, Martin H.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[37] FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Valle, Juan W.
Morizane, Chigusa
Karasic, Thomas Benjamin
Furuse, Junji
He, Yaohua
Soni, Nital
Benhadji, Karim A.
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[38] First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Yen, C. J.
Liu, M-C.
Fan, J.
Sun, C.
Peng, P.
Du, X.
Wang, J.
Wei, F.
Gou, Z.
Tan, X.
Wu, D.
Wu, F.
Ho, C-L.
ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
[39] A phase III study of INCB054828 as adjuvant therapy in patients (pts) with high-risk urothelial carcinoma (UC) harboring fibroblast growth factor receptor 3 (FGFR3) genomic alterations
Necchi, A.
Perez-Gracia, J. L.
Loriot, Y.
Witjes, W.
Montorsi, F.
Bjartell, A.
Shariat, S. F.
ANNALS OF ONCOLOGY, 2018, 29
[40] A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC).
Piha-Paul, Sarina A.
Hierro, Cinta
Matos, Ignacio
Boni, Valentina
Hahn, Noah
Bitting, Rhonda
Bauer, Todd
Rahul, Aggarwal
Meric-Bernstam, Funda
Gourlay, Steven
Owens, Timothy D.
Brameld, Ken
Neale, Ann
Schwartz, Richard
Murray, Steve
Ucpinar, Sibel
Foote, Peter
Venetsanakos, Eleni
Tabernero, Josep
CLINICAL CANCER RESEARCH, 2020, 26 (15) : 40 - 41

← 1 2 3 4 5 →